Eris Lifesciences Limited has informed the Exchange that Record date for the purpose of Dividend is 29-May-2026.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences reported strong FY2026 consolidated results with net profit after tax of Rs 647.51 Crores, up 72.8% from Rs 374.67 Crores in FY2025. Revenue from operations grew to Rs 3,129.42 Crores from Rs 2,893.64 Crores. Operating margin expanded to 27.11% from 24.89% in the prior year. The Board declared an interim dividend of Rs 7.21 per share (721% on Re. 1 face value) for FY2026-27, with record date May 29, 2026 and payment by June 19, 2026. An exceptional item of Rs 17.24 Crores was recorded due to new labour code implementation. Auditors Walker Chandiok & Co LLP issued unmodified opinions on both standalone and consolidated financials. The company also completed acquisition of remaining minority stake in Swiss Parenterals Limited during the year.
Strong profit growth and margin expansion signal operational efficiency improvements. The 72.8% PAT growth significantly ahead of typical thresholds is positive for shareholders. Clean audit opinions and healthy debt metrics (debt-equity ratio at 0.61x) support financial stability.